JAK2, Active(J02-11G)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :Recombinant human JAK2 (804-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Species :Human
Tag :GST tag
Expression System:Sf9 insect cells using baculovirus
Sequence :804-end
Genbank Number :NM_004972
Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Applications :Kinase Assay, Western Blot
Molecular Weight :~63 kDa
Gene Aliases :none
Scientific Background :JAK2 is a member of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway (1). JAK2 has two near-identical phosphate-transferring domains. One domain exhibits the kinase activity while the other stabilizes the JAK conformational structure. JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin. JAK2 has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon (2).
References :
1. Lacronique, V. Et al : A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 1997; 278: 1309-1312.
2. Ho, J.M. et al: TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood, 2002; 100: 1438-1448.
RESTRICTION :All orders for customers in the USA must be placed directly through SignalChem (This product cannot be purchased through Distributors in the USA). This product shall not be used to commercially screen drug molecules being developed as JAK1 or JAK2 inhibitors nor for any in vitro diagnostic purposes. Any such activity will be outside the scope of the research use only label license. The product is protected by the following patents: US5,910,426; US5,852,184; US5,821,069; US5,716,818,US5,658,791.
Product Sheets (By Lot #) :
Research Areas :Cancer, Cardiovascular Disease, Cytoplasmic Tyrosine Kinases, Inflammation, JAK/STAT Pathway, Cancer, Inflammation, Cardiovascular Disease, JAK/STAT Pathway, Cytoplasmic Tyrosine Kinases